ETFS

Manchester United (NYSE:MANU – Get Rating) is one of 33 public companies in the “Amusement & recreation services” industry, but how does it weigh in compared to its rivals? We will compare Manchester United to related companies based on the strength of its valuation, profitability, dividends, analyst recommendations, earnings, risk and institutional ownership. Volatility &

Brokerages forecast that Shenandoah Telecommunications (NASDAQ:SHEN – Get Rating) will report sales of $64.25 million for the current fiscal quarter, according to Zacks Investment Research. Three analysts have provided estimates for Shenandoah Telecommunications’ earnings. The lowest sales estimate is $63.00 million and the highest is $65.15 million. Shenandoah Telecommunications reported sales of $60.70 million during

NXP Semiconductors (NASDAQ:NXPI – Get Rating) has earned an average rating of “Buy” from the twenty-one brokerages that are presently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, six have given a hold recommendation, nine have issued a buy recommendation and one has assigned a strong

Wall Street analysts expect Enthusiast Gaming Holdings Inc. (NASDAQ:EGLX – Get Rating) to report $38.82 million in sales for the current fiscal quarter, Zacks Investment Research reports. Two analysts have made estimates for Enthusiast Gaming’s earnings, with estimates ranging from $37.88 million to $39.76 million. Enthusiast Gaming posted sales of $30.17 million during the same

Apple (NASDAQ:AAPL – Get Rating) has been given a $157.00 price objective by analysts at The Goldman Sachs Group in a report issued on Friday, Borsen Zeitung reports. The Goldman Sachs Group’s price objective indicates a potential upside of 7.60% from the stock’s previous close. Other equities research analysts have also issued reports about the

Hawkins (NASDAQ:HWKN – Get Rating) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a note issued to investors on Thursday, Zacks.com reports. According to Zacks, “Hawkins, Inc. distributes, blends and manufactures bulk and specialty chemicals and other health and nutrition products for its customers in a wide variety

Kirkland’s (NASDAQ:KIRK – Get Rating) was downgraded by equities research analysts at TheStreet from a “c” rating to a “d+” rating in a report released on Tuesday, TheStreetRatingsTable reports. Other equities research analysts have also recently issued reports about the company. Benchmark cut their target price on Kirkland’s from $25.00 to $15.00 and set a

Equities research analysts predict that Kymera Therapeutics, Inc. (NASDAQ:KYMR – Get Rating) will post earnings per share of ($0.67) for the current fiscal quarter, Zacks Investment Research reports. Six analysts have provided estimates for Kymera Therapeutics’ earnings, with estimates ranging from ($0.80) to ($0.58). Kymera Therapeutics posted earnings of ($0.55) per share in the same

Nautilus Biotechnology (NASDAQ:NAUT – Get Rating) is one of 42 publicly-traded companies in the “Analytical instruments” industry, but how does it compare to its rivals? We will compare Nautilus Biotechnology to related companies based on the strength of its profitability, earnings, analyst recommendations, valuation, dividends, risk and institutional ownership. Earnings and Valuation Get Nautilus Biotechnology

NeoGames (NASDAQ:NGMS – Get Rating) is one of 33 publicly-traded companies in the “Amusement & recreation services” industry, but how does it contrast to its peers? We will compare NeoGames to related businesses based on the strength of its earnings, dividends, risk, analyst recommendations, institutional ownership, profitability and valuation. Valuation and Earnings Get NeoGames alerts:

Brokerages expect ArcBest Co. (NASDAQ:ARCB – Get Rating) to report $3.86 earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Three analysts have provided estimates for ArcBest’s earnings, with estimates ranging from $3.67 to $4.06. ArcBest reported earnings per share of $1.97 during the same quarter last year, which would

Fujitsu (OTCMKTS:FJTSY – Get Rating) and Jungheinrich Aktiengesellschaft (OTCMKTS:JGHAF – Get Rating) are both computer and technology companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, analyst recommendations, dividends, earnings, profitability, valuation and institutional ownership. Analyst Recommendations Get Fujitsu alerts: This is a breakdown

Analysts expect that Amyris, Inc. (NASDAQ:AMRS – Get Rating) will post earnings per share of ($0.22) for the current fiscal quarter, Zacks reports. Five analysts have provided estimates for Amyris’ earnings, with the highest EPS estimate coming in at ($0.10) and the lowest estimate coming in at ($0.38). Amyris reported earnings of ($0.16) per share

Better Therapeutics (NASDAQ:BTTX – Get Rating) and Accelera Innovations (OTCMKTS:ACNV – Get Rating) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, dividends, earnings and risk. Risk and Volatility Get Better Therapeutics alerts: Better Therapeutics has

Analysts expect that CoreCivic, Inc. (NYSE:CXW – Get Rating) will report earnings per share (EPS) of $0.36 for the current fiscal quarter, Zacks Investment Research reports. Three analysts have made estimates for CoreCivic’s earnings, with estimates ranging from $0.33 to $0.38. CoreCivic reported earnings per share of $0.46 in the same quarter last year, which

Oatly Group (NASDAQ:OTLY – Get Rating) is one of 31 publicly-traded companies in the “Food & kindred products” industry, but how does it weigh in compared to its competitors? We will compare Oatly Group to similar businesses based on the strength of its profitability, valuation, analyst recommendations, dividends, institutional ownership, risk and earnings. Profitability Get

Wall Street analysts expect Aldeyra Therapeutics, Inc (NASDAQ:ALDX – Get Rating) to report earnings of ($0.32) per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Aldeyra Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.29) and the lowest estimate coming in at ($0.36). Aldeyra Therapeutics

A shorter version of this article appeared in the April 25, 2017 issue of Forbes. It’s spring: Corporate proxies are in the mail. Are these a noble exercise in shareholder democracy? Or an expensive farce? If you own corporate shares directly, your mailbox will soon fill up with ballots for directors and auditors. Should you